11/05/2019 03:50:00

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAPL, ARA, INVVY, ORN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, May 10, 2019 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

American Renal Associates Holdings, Inc. (ARA)

Class Period: 8/10/2016 - 3/27/2019

Lead Plaintiff Motion Deadline: May 27, 2019

SECURITIES FRAUD

To learn more, visit https://www.ksfcounsel.com/cases/nyse-ara/

Orion Group Holdings, Inc. (ORN)

Class Period: 3/13/2018 - 3/26/2019

Lead Plaintiff Motion Deadline: June 10, 2019

SECURITIES FRAUD

To learn more, visit https://www.ksfcounsel.com/cases/nyse-orn/

Apple Inc. (AAPL)

Class Period: 11/2/2018 - 1/2/2019

Lead Plaintiff Motion Deadline: June 17, 2019

SECURITIES FRAUD

To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-aapl/

Indivior PLC (INVVY))

Class Period: 3/10/2015 - 4/9/2019

Lead Plaintiff Motion Deadline: June 24, 2019

SECURITIES FRAUD

To learn more, visit https://www.ksfcounsel.com/cases/otc-invvy/ 

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email (Lewis.Kahn@KSFcounsel.com), or via the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About

Kahn Swick & Foti, LLC, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

lewis.kahn@ksfcounsel.com

1-877-515-1850

1100 Poydras St., Suite 3200

New Orleans, LA 70163

KSF-Logo.png

Related content
14 Jun - 
Bronstein, Gewirtz & Grossman, LLC Class Action Reminde..
14 Jun - 
FILING DEADLINE--Kuznicki Law PLLC Announces Class Acti..
13 Jun - 
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Enc..
Related debate
12 Jun - 
Det har danskerne ikke nogen indflydelse på, det er en ..
11 Jun - 
Tja.... Nu giver de jo ingen begrundelse, så indtil man..
11 Jun - 
Fake info... men i øvrigt også for sent hvis du ville p..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Jun
AAPL
Dansk burokrati og udsigt til højere skatter -  Ævl og bøvl uden ende når noget skal ske i Danmark
4
11 Jun
AAPL
Appel har selvfølgelig fået kolde fødder efter Mette Fredriksen er kommet til magten. Store energi..
3
11 Jun
AAPL
Eller så har Apple fundet ud af, at danskerne ikke ønsker at betale for deres fremtidig el-regning.
3
11 Jun
AAPL
Det er vel de rødes skyld *S*
3
11 Jun
AAPL
  Tja.... Nu giver de jo ingen begrundelse, så indtil man kender grunden så er der ingen grund til a..
2
11 Jun
AAPL
Åndsformørket sludder, Danmark er et stabilt demokrati og det kan ikke være nogen nyhed for Apple, a..
2
11 Jun
AAPL
Det bliver Venezuela 2
2
11 Jun
AAPL
Vi taber intet her. Der går bare 1/1000 sekund mere fra Aabenraa til Viborg og så liggr det på lager..
1
11 Jun
AAPL
co2 fri strøm og gratis i 10 år...giv dem dog for pokker en slagvare, der vil noget. Så løfter vi pr..
1
11 Jun
AAPL
Det var så bare ikke bureaukrati eller skatter der er årsag til Apple's ændring af pracering af data..
1

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
5
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

Related stock quotes

Apple Inc 192.74 -0.7% Stock price decreasing
Orion Group Holdings Inc.. 2.160 -2.3% Stock price decreasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 10:50:35
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB4 - 2019-06-16 11:50:35 - 2019-06-16 10:50:35 - 1000 - Website: OKAY